# Butterfly Network, Inc.: Form 10-Q for the period ended Mar 31, 2022

- Company: [Butterfly Network, Inc.](/companies/bfly.md) (CIK 1804176)
- Form: 10-Q
- Filed: 2022-05-06
- Accepted by EDGAR: May 6, 2022, 16:16 ET
- Period: 2022-03-31
- Accession: 0001558370-22-007630
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1804176/000155837022007630/tmb-20220331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1804176/000155837022007630/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-01 to 2022-03-31 | $15.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-01-01 to 2022-03-31 | $7.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-01-01 to 2022-03-31 | $8.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-01-01 to 2022-03-31 | $23.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-01-01 to 2022-03-31 | −$49.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-01-01 to 2022-03-31 | $17.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-01 to 2022-03-31 | −$44.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-01-01 to 2022-03-31 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-01-01 to 2022-03-31 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-01-01 to 2022-03-31 | 199,000,258 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2022-01-01 to 2022-03-31 | −$54.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-01 to 2022-03-31 | $4.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-03-31 | $359.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $474.3m | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $535.4m | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $50.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $122.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-03-31 | $412.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,277 characters.

*The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto for the year ended December 31, 2021 contained in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three months ended March 31, 2022 and 2021, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.*

### Overview

We are an innovative digital health business transforming care with hand-held, whole body ultrasound. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional’s pocket with a unique combination of cloud-connected software and hardware technology that is easily accessed through a mobile app.

Butterfly iQ+ is an ultrasound transducer that can perform whole-body imaging in a single handheld probe using semiconductor technology. Our Ultrasound-on-Chip™ makes ultrasound more accessible outside of large healthcare institutions, while our software is intended to make the product easy to use and fully integrated with the clinical workflow, accessible on a user’s smartphone, tablet, and almost any hospital computer system connected to the Internet. Butterfly aims to enable the delivery of imaging information anywhere at point-of-care to drive earlier detection throughout the body and remote management of health conditions. We market and sell the Butterfly system, which includes probes and related accessories and software subscriptions, to healthcare systems, physicians and healthcare providers through a direct sales force, distributors and our eCommerce channel.

### COVID-19

The COVID-19 pandemic that began in 2020 has created significant global economic uncertainty. Uncertainty remains regarding the extent, timing and duration of the pandemic, including the emergence of new strains of the virus that may be more contagious or virulent and the extent to which the availability of vaccines and other safety measures will positively impact public health conditions. The uncertainty and potential economic volatility impact our customer base, supply chains, business practices and employees.

The COVID-19 pandemic and its economic impact have caused financial strain on our customer base due to decreased funding and other revenue shortfalls. During the pandemic, we have seen our customer base become further strained in solving immediate problems associated with the variants. As a result, some of our customers have had to shift their attention to these pressing issues, resulting in longer sales cycles and slower adoption in the near term.

In addition, the issues originally brought on by COVID-19 continue to have an ongoing adverse impact on global supply chains, including ours. We have experienced constraints in availability, increasing lead times and costs required to obtain some inventory components; however, the semiconductor chips used in our probes are manufactured under an inventory supply agreement and to date we have not experienced any constraints. We have and will continue to implement operating efficiencies in our supply chain and manufacturing processes to help offset the cost increases in component parts for our device.

The pandemic caused us to make modifications to our business practices, including work from home policies, establishing strict health and safety protocols for our offices specific to COVID-19 and imposing restrictions on employee travel. Our employees have resumed traveling to perform sales-generating and corporate activities, and we have opened our offices and have allowed employees at their discretion to return to our offices. We are designing and implementing a plan to allow employees safely to resume work in the office on a more regular basis.

We continue to closely monitor the developments of COVID-19 for any material impact on our business. Given the uncertainty and potential economic volatility of the impact of the COVID-19 pandemic, the developments we have experienced may change based on new information that may emerge concerning COVID-19, its economic impact on local, regional, national and international markets and the actions to contain it or address its impacts.

### Key Performance Metrics

We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions. Our key performance metrics may fluctuate over time as the adoption of our devices increases which may shift the revenue mix more toward subscriptions. The quarterly metrics may be impacted by the timing of device sales.

### Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.

Units fulfilled increased by 93, or 1.9%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to increased sales from our veterinary, distributor and direct sales force channels. The increase was partially offset by slowing sales in our e-commerce channel.

### Subscription Mix

We define subscription mix as a percentage of our total revenue recognized in a reporting period that is subscription-based, consisting primarily of our software as a service (“SaaS”) offering. We view subscription mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors. Because the costs and associated expenses to deliver our subscription offerings are lower as a percentage of sales than the costs of sales of our products, we believe a shift towards subscription will result in an improvement in profitability and margin expansion.

Subscription mix increased by 6.4 percentage points, to 29.3% for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase was due to a higher volume of units fulfilled since the prior year quarter and increases in subscription renewals. In addition, the increase is due to the timing of revenue recognition for our SaaS and other subscription contracts as revenue from such contracts is deferred and recognized over the service period.

### Non-GAAP Financial Measures

We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

Our Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA alongside other financial performance measures prepared in accordance with U.S. GAAP, including gross profit, gross margin, operating loss and net loss.

### Adjusted Gross Profit and Adjusted Gross Margin

We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs. We calculate Adjusted Gross Margin as gross margin adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs.

Our changes in the warranty liability are excluded from Adjusted Gross Profit and Adjusted Gross Margin when they are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

We also exclude from Adjusted Gross Profit and Adjusted Gross Margin non-recurring losses on purchase commitments and non-recurring inventory write-downs when they are outside the normal course of business and in the period the expenses are incurred. The periods shown below do not include such expenses.

The following table reconciles Adjusted Gross Profit to gross profit and Adjusted Gross Margin to gross margin, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

*(In thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ Three months ended March 31, 2022 | ​ ​ | ​ ​ 2021 |
| --- | --- | --- | --- | --- |
| Revenue |  | $15,574 | ​ | $12,443 |
| Cost of revenue | ​ | 7,232 | ​ | 6,027 |
| **Gross profit** | **​** | **$8,342** | **​** | **$6,416** |
| ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Gross margin** | **​** | **​** **53.6%** | **​** | **​** **51.6%** |
| ​ | ​ | ​ ​ | ​ | ​ ​ |
| Add: | ​ |  | ​ |  |
| Depreciation and amortization | ​ | 426 | ​ | 89 |
| Warranty liability policy change | ​ | ​ — | ​ | ​ (560) |
| **Adjusted gross profit** | **​** | **$8,768** | **​** | **$5,945** |
| **​** | **​** | **​** **​** | **​** | **​** **​** |
| **Adjusted gross margin** | **​** | **​** **56.3%** | **​** | **​** **47.8%** |

### Adjusted EBITDA

We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, changes in the fair value of warrant liabilities, other expense, net, provision for income taxes, stock-based compensation, depreciation and amortization and other non-recurring items. The other non-recurring items include costs related to our executive transition, adjustments for the warranty liability policy changes, discretionary transaction bonuses, non-recurring losses on purchase commitments, non-recurring inventory write-downs and other fees incurred with the close of the Business Combination.

Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts and the non-recurring inventory write-down adjustments are for excess and obsolete inventory resulting from a shift in product lines. The periods shown below do not include such expenses.

The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.

*(In thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ Three months ended March 31, 2022 | ​ ​ | ​ ​ 2021 | ​ ​ ​ |
| --- | --- | --- | --- | --- | --- |
| **Net loss** |  | **$(44,477)** |  | **$(690)** | **​** |
| Interest income |  | ​ (10) |  | ​ (239) | ​ |
| Interest expense |  | ​ — |  | ​ 638 | ​ |
| Change in fair value of warrant liabilities | ​ | ​ (5,163) | ​ | ​ (54,112) | ​ |
| Other expense, net |  | ​ 100 |  | ​ 631 | ​ |
| Provision for income taxes |  | ​ 17 |  | ​ 24 | ​ |
| Stock based compensation |  | ​ 8,730 |  | ​ 20,298 | ​ |
| Depreciation and amortization |  | ​ 839 |  | ​ 458 | ​ |
| CEO transition costs | ​ | ​ — | ​ | ​ 5,398 | ​ |
| Warranty liability policy change | ​ | ​ — | ​ | ​ (560) | ​ |
| Transaction bonus | ​ | ​ — | ​ | ​ 1,653 | ​ |
| **Adjusted EBITDA** |  | **$(39,964)** |  | **$(26,501)** | **​** |

### Description of Certain Components of Financial Data

### Revenue

Revenue consists of revenue from the sale of products, such as medical devices and accessories, and related services, classified as subscription revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and product support and maintenance (“Support”). SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products, which include the ultrasound devices and any ultrasound device accessories, revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.

Over time as the adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward subscriptions. The quarterly revenue mix may be impacted by the timing of device sales.

### Cost of revenue

Cost of product revenue consists of product costs including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and decrease as a percentage of product revenues over time as we focus on operational efficiencies in our supply chain. Additionally, we expect there will continue to be supply constraints; however, the semiconductor chips used in our probes are manufactured under an inventory supply agreement and to date we have not experienced any constraints. Our suppliers have and may from time-to-time increase prices of certain inventory components, which we may not be able to offset through pricing actions and therefore could in the future offset the operational efficiencies in our supply chain.

Cost of subscription revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate an improvement in profitability and margin expansion over time as our revenue mix shifts increasingly towards subscriptions. We plan to continue to invest additional resources into our products to expand and further develop our SaaS and other subscription offerings. The level and timing of investment in these areas could affect our cost of subscription revenue in the future. We expect the cost of subscription revenue to increase as a percentage of subscription revenue in the near term due to the investments we are making, but will continue to be lower than the cost of product revenue as a percentage of product revenue.

Loss on product purchase commitments relates to inventory supply agreements where the expected losses exceed the benefit of the contracts. We consider a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points include Company-specific forecasts which are reliant on our limited sales history, agreement-specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates. Future events may differ from those assumed in our assessment, and therefore the loss may change in the future. The Company did not incur any losses on product purchase commitments during the three months ended March 31, 2022 and 2021.

### Research and development (R&D)

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services, which we define as not having reached the point of commercialization and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities. Prospectively on an annual basis, we expect research and development spending to increase in absolute dollars in the near term and then fluctuate over time due to the level and timing of our product development efforts. In the near term, we expect research and development expenses as a percentage of revenue to increase on an annual basis.

### Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, digital marketing, advertising, promotional, as well as conferences, meetings and other events and related facilities and information technology costs. We expect our sales and marketing expenses to increase in absolute dollars in the long term as we continue to increase the size of our direct sales force and sales support personnel and expand into new products and markets. We expect our sales and marketing expenses will also increase in the near term as we promote our brand through marketing and advertising initiatives, expand our market presence and hire additional personnel to drive penetration and generate leads. In the near term, sales and marketing expenses as a percentage of revenues may increase on an annual basis and then fluctuate over time as we evaluate expansion opportunities.

### General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, insurance, patent fees, software costs, facilities costs and outside services. Outside services consist of professional services, legal and other professional fees. We expect our general and administrative expenses to increase in absolute dollars in the foreseeable future. In the near term, we anticipate general and administrative expenses as a percentage of revenue will decrease on an annual basis.

### Results of Operations

We operate as a single reportable segment to reflect the way our chief operating decision maker (“CODM”) reviews and assesses the performance of the business. The accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

*(in thousands)*

| ​ ​ ​ ​ Revenue: | ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2022 ​ ​ Dollars | ​ ​ ​ | ​ ​ ​ % of ​ revenue ​ | ​ ​ ​ ​ | ​ ​ 2021 ​ ​ Dollars | ​ ​ ​ | ​ ​ % of revenue | ​ ​ ​ ​ ​ |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Product | ​ | $11,014 |  | 70.7% | ​ | $9,595 |  | 77.1% | ​ |
| Subscription | ​ | ​ 4,560 |  | 29.3% | ​ | ​ 2,848 |  | 22.9% | ​ |
| **Total revenue:** | ​ | $15,574 |  | 100.0% | ​ | $12,443 |  | 100.0% | ​ |
| Cost of revenue: | ​ | ​ |  |  | ​ | ​ |  | ​ | ​ |
| Product | ​ | ​ 6,149 |  | 39.5% | ​ | ​ 5,648 |  | 45.4% | ​ |
| Subscription | ​ | ​ 1,083 |  | 7.0% | ​ | ​ 379 |  | 3.0% | ​ |
| **Total cost of revenue:** | ​ | $7,232 |  | 46.4% | ​ | $6,027 |  | 48.4% | ​ |
| **Gross profit** | **​** | **$8,342** |  | 53.6% | ​ | **$6,416** |  | 51.6% | **​** |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| Operating expenses: | ​ | ​ |  |  | ​ | ​ |  | ​ | ​ |
| Research and development | ​ | ​ 23,623 |  | 151.7% | ​ | ​ 15,716 |  | 126.3% | ​ |
| Sales and marketing | ​ | ​ 15,202 |  | 97.6% | ​ | ​ 9,808 |  | 78.8% | ​ |
| General and administrative | ​ | ​ 19,050 |  | 122.3% | ​ | ​ 34,640 |  | 278.4% | ​ |
| **Total operating expenses** | **​** | **$57,875** |  | 371.6% | ​ | **$60,164** |  | 483.5% | **​** |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| **Loss from operations** | **​** | **$(49,533)** |  | (318.0)% | **​** | **$(53,748)** |  | (432.0)% | **​** |
| Interest income | ​ | ​ 10 |  | 0.1% | ​ | ​ 239 |  | 1.9% | ​ |
| Interest expense | ​ | ​ — |  | —% | ​ | ​ (638) |  | (5.1)% | ​ |
| Change in fair value of warrant liabilities | ​ | ​ 5,163 | ​ | 33.2% | ​ | ​ 54,112 | ​ | 434.9% | ​ |
| Other income (expense), net | ​ | ​ (100) |  | (0.6)% | ​ | ​ (631) |  | (5.1)% | ​ |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| **Loss before provision for income taxes** | **​** | **$(44,460)** |  | (285.5)% | ​ | **$(666)** |  | (5.4)% | **​** |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| Provision for income taxes | ​ | ​ 17 |  | 0.1% | ​ | ​ 24 |  | 0.2% | ​ |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| **Net loss** | **​** | **$(44,477)** |  | (285.6)% | ​ | **$(690)** |  | (5.5)% | **​** |

### Comparison of the three months ended March 31, 2022 and 2021

### Revenue

*(in thousands)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Three months ended March 31, 2022 ​ | ​ ​ | ​ ​ 2021 ​ | ​ ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Product |  | $11,014 | ​ | $9,595 | ​ | $1,419 | 14.8% |
| Subscription |  | ​ 4,560 | ​ | ​ 2,848 | ​ | ​ 1,712 | 60.1% |
| Total revenue: | ​ | $15,574 | ​ | $12,443 | ​ | $3,131 | 25.2% |

Product revenue increased by $1.4 million, or 14.8%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase in product revenue was primarily driven by higher prices of products sold due to a price increase in the third quarter of fiscal 2021 and, to a lesser extent, a higher volume of probes sold.

Subscription revenue increased by $1.7 million, or 60.1%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase was driven by a higher volume of our SaaS subscriptions sold in conjunction with sales of our devices, as well as the current year subscription renewals.

### Cost of revenue

*(in thousands)*

| ​ ​ Cost of revenue: | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2022 ​ ​ | ​ ​ ​ ​ 2021 ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | ---: | ---: | ---: |
| Product |  | $6,149 ​ | $5,648 ​ | $501 | 8.9% |
| Subscription |  | ​ 1,083 ​ | ​ 379 ​ | ​ 704 | 185.8% |
| Total cost of revenue: | ​ | $7,232 ​ | $6,027 ​ | $1,205 | 20.0% |
| Percentage of revenue | ​ | 46.4% | 48.4% |  | ​ |

Cost of product revenue increased by $0.5 million, or 8.9%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase was primarily driven by $0.5 million of higher warranty expense due to the prior year change in our warranty liability policy, higher inventory write-offs of $0.3 million and increases in component costs related to global supply chain constraints of $0.3 million. These increases were partially offset by a benefit from operational efficiencies of $0.8 million.

Cost of subscription revenue increased by $0.7 million, or 185.8%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This increase was primarily driven by increased cloud hosting costs and amortization expenses.

### Research and development

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2022 ​ | ​ ​ ​ ​ 2021 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development |  | $23,623 | $15,716 | $7,907 | 50.3% |
| Percentage of revenue | ​ | 151.7% | 126.3% |  | ​ |

Research and development expenses increased by $7.9 million, or 50.3%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This increase was primarily driven by higher personnel costs, including stock-based compensation expense, of $5.0 million, product development supplies of $0.9 million, software costs of $0.7 million and professional service fees of $0.8 million as we continue to invest in expanding our overall product development capabilities and resources.

### Sales and marketing

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2022 ​ | ​ ​ ​ ​ 2021 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Sales and marketing |  | $15,202 | $9,808 | $5,394 | 55.0% |
| Percentage of revenue | ​ | 97.6% | 78.8% |  | ​ |

Sales and marketing expenses increased by $5.4 million, or 55.0%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This increase was primarily driven by higher personnel costs, including stock-based compensation, of $3.9 million, overhead costs of $0.4 million and travel and entertainment costs of $1.0 million primarily related to the Company’s annual sales conference and trade show participation.

### General and administrative

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2022 ​ | ​ ​ ​ ​ 2021 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| General and administrative |  | $19,050 | $34,640 | $(15,590) | (45.0)% |
| Percentage of revenue | ​ | 122.3% | 278.4% |  | ​ |

General and administrative expenses decreased by $15.6 million, or 45.0%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This decrease was primarily due to lower personnel costs of $12.6 million driven by a reduction in stock-based compensation due to the non-recurrence of certain performance based restricted stock units that vested upon the Closing of the Business Combination in the prior year, lower recruiting expense of $1.7 million from the non-recurrence of certain costs associated with to our CEO transition, and lower professional service fees of $1.8 million as we scale up our internal capabilities.

### Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations, proceeds from the Business Combination and issuances of preferred stock and convertible notes. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have been historically negative as we continue to develop new products and services and increase our sales and marketing efforts. We expect to be cash flow negative on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect that our existing cash and cash flows from operations will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months.

Our cash and cash equivalents balance as of March 31, 2022 was $359.9 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.

We have restricted cash of $4.0 million as of March 31, 2022 to secure a letter of credit for one of our leases, which is expected to be maintained as a security deposit for the duration of the lease. In addition, we have restricted cash of $4.8 million for a grant issued by the Bill & Melinda Gates Foundation (“BMGF”). The restriction is expected to lapse as we fulfill our obligations in the contractual agreement with BMGF.

The nature of the Company’s cash requirements has not changed materially during the three months ended March 31, 2022. Our material cash requirements include our facility lease arrangements for office space and inventory purchase obligations. As of March 31, 2022, we had fixed lease payment obligations of $42.1 million, with $2.5 million payable within 12 months. As of March 31, 2022, we had fixed purchase obligations of $103.8 million, with $65.9 million payable within 12 months. We expect to pay for approximately half of the fixed purchase obligations payable within the next 12 months using vendor advances.

As of March 31, 2022, we had no obligations, assets or liabilities, which would be considered off-balance sheet arrangements.

### Cash flows

### Comparison of the period for the three months ended March 31, 2022 and March 31, 2021

The following table summarizes our sources and uses of cash for the three months ended March 31, 2022 and 2021:

*(in thousands)*

| ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2022 | ​ ​ ​ ​ 2021 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(54,234) | $(63,427) |
| Net cash used in investing activities | ​ (4,506) | ​ (528,197) |
| Net cash provided by financing activities | ​ 550 | ​ 550,268 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(58,190) | $(41,356) |

### Net cash used in operating activities

Net cash used in operating activities represents the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by historical financing activities will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.

Net cash used in operating activities decreased by $9.2 million, or 14.5%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The decrease in net cash used in operating activities was due to a $5.2 million decrease in cash used in vendor advances resulting from the usage of the advance for purchases of inventory components during the period, a $14.0 million decrease in cash used for accounts payable and accrued expenses due to the timing of expenses and payments and deferred grant funding, which was partially offset by an increase in cash used for inventory purchases of $1.8 million due to timing and an increase of $1.8 million for accounts receivable due to increased sales. Additionally, there was a $37.0 million decrease in adjustments to reconcile net loss partially offset by a $43.8 million increase in net losses. The adjustments were primarily related to changes in the fair value warrant liability and less stock-based compensation incurred.

### Net cash used in investing activities

Net cash used in investing activities decreased by $523.7 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The decrease was primarily due to a decrease of $526.9 million in purchases and sales of marketable securities for the period ended March 31, 2022. The decrease was partially offset by an increase in purchases of property and equipment of $3.2 million due to additional assets purchased for the Company’s office space and additional investments into our software platform.

### Net cash provided by financing activities

For the three months ended March 31, 2022, net cash provided by financing activities decreased by $549.7 million compared to the three months ended March 31, 2021. The decrease was primarily due to the non-recurrence of net proceeds from the Business Combination of $548.4 million and a decrease in proceeds from option exercises of $5.6 million, which was partially offset by the non-recurrence of the $4.4 million loan repayment under the Paycheck Protection Program.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as amended.

### Recently Adopted Accounting Pronouncements

The Company did not identify any significant recently issued accounting pronouncements that may potentially impact our financial position and results of operations.

## Market risk

As filed, 1,217 characters.

### Interest Rate Risk

We did not have any floating rate debt as of March 31, 2022. Our cash and cash equivalents are comprised primarily of bank deposits and money market accounts. Due to the short-term nature of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

### Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations, other than its impact on the general economy. Nonetheless, to the extent our costs are impacted by general inflationary pressures, we may not be able to fully offset such higher costs through price increases or manufacturing efficiencies. Our inability or failure to do so could harm our business, financial condition and results of operations.

### Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

## Controls and procedures

As filed, 1,761 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2022.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 459 characters.

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on February 28, 2022, as amended on March 28, 2022 and April 19, 2022 (the “2021 Annual Report on Form 10-K”). There have been no material changes to the risk factors described in the 2021 Annual Report on Form 10-K.

Filed May 6, 2022.
Source: SEC EDGAR, the filing index for accession 0001558370-22-007630. Last ingested by Listed: Nov 14, 2026, 23:40 ET. No prices; not investment advice.
